Public company, workplace, funding, and market signals
Updated Jul 30, 2026
Oncology-focused AI software company that reads longitudinal patient records and turns them into cited, auditable outputs for trial matching, visit preparation, and registry/data curation at cancer centers.
Primary product
OncoLLM-powered oncology workflow platform (PRISM, Symphony, Harmony)
Founded
2021
Headquarters
1 World Trade Center, Ste. 46C, New York, NY 10007, United States
Team size
50-60
Industry
Software Development
Sub-industry
Oncology AI / clinical workflow automation
Offices
Business model
Stage
Series B
Total raised
$54.2M
Latest round
Series B · May 2026
Latest amount
$22M
May 2026 · Battery Ventures
Jul 2024 · PharmStars
May 2024 · Lightspeed
Nov 2021 · Nexus Venture Partners
Mar 2021 · Y Combinator
Leadership
Co-founder & CEO
Co-founder & CTO
Chief Business Officer
Chief Data Officer
Director of Machine Learning
Director of Product Management
Director of Analytics
Design Director
Mark Steiner
Vice President, Head of Partnerships
Yeswanth Tadikamalla
Head of Engineering
Paul Deleanu
Director of Compliance
Mission-driven and oncology-focused; emphasizes clear written communication, ownership, responsible innovation, and a calm/durable pace, while job posts also describe a fast-paced, ownership-driven startup environment.
Compensation
US roles list roughly $80k-$200k/year depending on role; Bengaluru roles are advertised as 'best-in-industry' with no range disclosed.
Benefits
Pricing
Enterprise B2B software with custom contracts; some deployments appear sponsor-supported or performance-based.
Differentiators
Technology
Customers
Competitors
Estimated revenue
$5.1M-$12.6M estimated annual revenue (third-party estimates vary; one source estimates ~$9.9M ARR)
Estimated monthly visits
11.7K
Traffic estimate as of Mar 2025
PRNewswire · May 2026
Official Series B announcement: $22M led by Battery Ventures, with participation from Nexus, Lightspeed, Y Combinator, Oncology Ventures, and Precision Health Informatics; total funding described as >$36M and customers include MSK, MD Anderson, Yale/Smilow, Mount Sinai, and Texas Oncology.
TechCrunch · May 2026
Reports the Series B, notes Triomics' product expansion from trial matching into visit preparation/patient summaries, and says the company grew enterprise customers 4x and annualized recurring revenue 10x in the prior year.
Mount Sinai Health System · Jan 2026
Mount Sinai newsroom item on launching Triomics-powered clinical trial matching to expand cancer research access.
PRNewswire · Nov 2025
Official rollout announcement for Connecticut/Yale-related clinical-trial screening deployment.
Memorial Sloan Kettering Cancer Center · Nov 2025
MSK announcement about deploying Triomics for clinical trial matching and screening.
0 jobs at Triomics
Check back later for new openings